G.J. Ossenkoppele

5.4k citations

84 papers · 3.3k indexed · h-index 34

Hematology top 0.5%
- Acute Myeloid Leukemia Research 28
- Hematopoietic Stem Cell Transplantation 12
- Chronic Myeloid Leukemia Treatments 8
Genetics top 1%
- Chronic Lymphocytic Leukemia Research 9
Pathology and Forensic Medicine top 1%
- Lymphoma Diagnosis and Treatment 19
Oncology top 2%
Biological Psychiatry top 5%
Public Health, Environmental and Occupational Health
- Acute Lymphoblastic Leukemia research 14
Immunology
- Immunotherapy and Immune Responses 9
- Immune Cell Function and Interaction 7

Co-authors: Arjan A. van de Loosdrecht N Feller Bob Löwenberg Gerrit Jan Schuurhuis Peter C. Huijgens Jeroen J. W. M. Janssen Pieter Sonneveld G. Verhoef
Cited by: Hematology Genetics Pathology and Forensic Medicine
Journals: Leukemia (21 papers)Blood (7 papers)Leukemia Research (6 papers)
Partner nations: Netherlands United States United Kingdom

In The Last Decade

G.J. Ossenkoppele

78 papers receiving 3.3k citations

Peers

Countries citing papers authored by G.J. Ossenkoppele

Since Specialization

Citations

This map shows the geographic impact of G.J. Ossenkoppele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G.J. Ossenkoppele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G.J. Ossenkoppele more than expected).

Fields of papers citing papers by G.J. Ossenkoppele

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G.J. Ossenkoppele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G.J. Ossenkoppele. The network helps show where G.J. Ossenkoppele may publish in the future.

Co-authorship network

The 25 scholars most cited alongside G.J. Ossenkoppele, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with G.J. Ossenkoppele Line = papers co-authored together G.J. Ossenkoppele links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia Leukemia ·Wendelien Zeijlemaker,Angèle Kelder,Yvonne J.M Oussoren-Brockhoff,Willemijn J. Scholten,Alexander N. Snel,Dennis Veldhuizen,Jacqueline Cloos,G.J. Ossenkoppele,Gerrit Jan Schuurhuis	2015	88
2	The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system Leukemia ·Canan Alhan,Theresia M. Westers,Eline M.P. Cremers,Claudia Cali,Birgit I. Lissenberg‐Witte,G.J. Ossenkoppele,Arjan A. van de Loosdrecht	2015	27
3	Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study Annals of Hematology ·Marjolein van der Poel,Wubbo J. Mulder,G.J. Ossenkoppele,E. Maartense,Mels Hoogendoorn,P. W. Wijermans,H.C. Schouten	2015	11
4	Improved risk stratification by the integration of the revised International Prognostic Scoring System with the Myelodysplastic Syndromes Comorbidity Index European Journal of Cancer ·Rongrong Liu,G.J. Ossenkoppele,Rebecca Holman,Arjan A. van de Loosdrecht	2014	18
5	High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2 Leukemia Research ·Martine E.D. Chamuleau,G.J. Ossenkoppele,Anna van Rhenen,河田雅圭,Anita Cabrera,Adri Zevenbergen,Gerrit‐Jan Schuurhuis,Arjan A. van de Loosdrecht	2011	33
6	Allogeneic stem cell transplantation as salvage therapy in patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem cell transplantation. An analysis of the EBMT Registry Bone Marrow Transplantation ·Faycel Kouteib,Carmen Canals,H. Schouten,Arnon Nagler,V. V. Kvasnyts’kyy,Sheren Viona,Vernant Jp,Agnès Buzyn,J. Maertens,J.J. Luan,Anne Uyttebroeck,Jialu Wen,Nöel Milpied,Rosanna Muralla,G.J. Ossenkoppele,Anna Sureda	2009	2
7	Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses Haematologica ·Marvin M. van Luijn,Martine E.D. Chamuleau,James A. Thompson,Suzanne Ostrand‐Rosenberg,Theresia M. Westers,Yuri Souwer,G.J. Ossenkoppele,S. Marieke van Ham,Arjan A. van de Loosdrecht	2009	21
8	Expression of TNF‐receptor associated factor 2 correlates with poor progression‐free survival time in ABC‐like primary nodal diffuse large B‐cell lymphomas Histopathology ·Joost C. van Galen,Jettie J.F. Muris,フリッツラウピヒラー,W Vos,G.J. Ossenkoppele,Chris J.L.M. Meijer,Joost J. Oudejans	2008	6
9	Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission Leukemia ·Anna van Rhenen,Bijan Moshaver,Angèle Kelder,N Feller,Aggie Nieuwint,Sonja Zweegman,G.J. Ossenkoppele,Gerrit‐Jan Schuurhuis	2007	144
10	MHC class II molecules in tumour immunology: Prognostic marker and target for immune modulation Immunobiology ·Martine E.D. Chamuleau,G.J. Ossenkoppele,Arjan A. van de Loosdrecht	2006	36
11	Profiling of caspase signalling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas (DLBCL) Annals of Oncology ·Jettie J.F. Muris,Saskia A.G.M. Cillessen,Susann Nordström,Tim Ruhe,G.J. Ossenkoppele,J. Han van Krieken,Chris J.L.M. Meijer,Joan Klam	2005	1
12	Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas Leukemia ·Jettie J.F. Muris,C J Meijer,Saskia A.G.M. Cillessen,W Vos,J. Alain Kummer,C. Boutoleau,M.J.J.T. Bogman,Marius MacKenzie,Natasha Jiwa,Matthijs L. Siegenbeek van Heukelom,G.J. Ossenkoppele,Joost J. Oudejans	2003	77
13	A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia Leukemia ·Amber van Stijn,Alice Kok,R. Hatim Muhammad Amin,N Feller,Z. Mazhar,August H. Westra,G.J. Ossenkoppele,Gerrit Jan Schuurhuis	2003	22
14	P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. PubMed ·Meehan Crist,Elisabeth G.E. de Vries,J. Sáenz de Ugarte Sobrón,Yasa Genck,G.J. Ossenkoppele,G. Verhoef,Edo Vellenga	2000	84
15	Stem Cell Transplantations in Patients with Malignant Lymphoma: Costs in a Dutch University Hospital in the Period 1984-1995 Journal of Hematotherapy & Stem Cell Research ·C.A. Uyl-de Groot,G.J. Ossenkoppele,Zhencai Sun,Peter C. Huijgens	1999	4
16	Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia ·H J Broxterman,Pieter Sonneveld,R. Pieters,J. Lankelma,CA Eekman,E D Gray,M. Schoester,G.J. Ossenkoppele,Bob Löwenberg,H. M. Pinedo,Sang-Oh Yoon	1999	34
17	Chronic myeloid leukemia from basics to bedside Leukemia ·S. F. T. Thijsen,GJ Schuurhuis,Berenice Bermudes-Valencia,G.J. Ossenkoppele	1999	45
18	A functional study on the migration of human monocytes to human leukemic cell lines and the role of monocyte chemoattractant protein-1 Leukemia ·Xiumei Luo,Я.В. Хоменко,Sang-Oh Yoon,Luisa Gonzato,魏崇辉,Janneke Tekstra,Yasuhiro TACHIBANA,G.J. Ossenkoppele	1997	10
19	Therapeutic potential of intravenous 67‐gallium in non‐Hodgkin's lymphoma European Journal Of Haematology ·Peter C. Huijgens,Andries R. Jonkhoff,O. S. Hoekstra,G.J. Ossenkoppele,G. J. J. Teule	1993	8
20	Longterm meningeal involvement as the only clinical manifestation of low grade malignant non-Hodgkin's lymphoma Journal of Neuro-Oncology ·J.J. Heimans,P. Wijermans,CH Polman,Peter C. Huijgens,G.J. Ossenkoppele,Gerard J. van Kamp	1990	3

About G.J. Ossenkoppele

G.J. Ossenkoppele is a scholar working on Hematology, Genetics, Pathology and Forensic Medicine, Immunology and Biological Psychiatry, having authored 84 papers that have together received 3.3k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (28 papers), Lymphoma Diagnosis and Treatment (19 papers), Acute Lymphoblastic Leukemia research (14 papers), Hematopoietic Stem Cell Transplantation (12 papers), Chronic Lymphocytic Leukemia Research (9 papers), Immunotherapy and Immune Responses (9 papers), Chronic Myeloid Leukemia Treatments (8 papers) and Immune Cell Function and Interaction (7 papers). The work is most often cited by research in Hematology (1.6k citations), Genetics (677 citations), Pathology and Forensic Medicine (812 citations), Oncology (1.1k citations) and Biological Psychiatry (79 citations). G.J. Ossenkoppele has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Arjan A. van de Loosdrecht, N Feller, Bob Löwenberg, Gerrit Jan Schuurhuis, Peter C. Huijgens, Jeroen J. W. M. Janssen, Pieter Sonneveld, G. Verhoef, Martine E.D. Chamuleau and Angèle Kelder. Their work appears in journals such as Leukemia, Blood, Leukemia Research, Haematologica and Bone Marrow Transplantation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact